Home » EC Approves BMS-Gilead AIDS Drug
EC Approves BMS-Gilead AIDS Drug
The European Commission (EC) has granted marketing authorization for Atripla, which was developed by Bristol-Myers Squibb (BMS) and Gilead.
Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is used to treat HIV-1 infection in adults.
The application was filed by a three-way joint venture based in Ireland called Bristol-Myers Squibb Gilead Sciences and Merck Sharp & Dohme Limited, Gilead said.
Efavirenz is marketed by BMS as Sustiva in the U.S., Canada and six European countries and by Merck through its affiliate Merck Sharp & Dohme as Stocrin in the European Union.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May